SCHEMBL8299549

SCHEMBL8299549

C=C(C)NCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 4/20 0.56
HPGD P15428 2/20 0.56
ALDH1A1 P00352 2/20 0.56
GAA P10253 4/20 0.54
MAPT P10636 3/20 0.54
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
POLB P06746 1/20 0.54
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52
IDO1 P14902 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.50
THRB P10828 1/20 0.50
CYP2C9 P11712 1/20 0.50
PTPN1 P18031 1/20 0.49
ALPL P05186 1/20 0.48
LMNA P02545 1/20 0.48
PKM P14618 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24347533 0.83 ALOX12 (0.52) ALOX12HPGDALDH1A1GAAMAPT
SCHEMBL14065008 0.81 ALOX12 (0.60) ALOX12HPGDALDH1A1GAAMAPT
SCHEMBL3343137 0.81 ALOX12 (0.67) ALOX12HPGDALDH1A1GAAMAPT
SCHEMBL5184971 0.81 ALOX12 (0.60) ALOX12HPGDALDH1A1GAAMAPT
SCHEMBL13369666 0.80 SMN1; SMN2 (0.53) HPGDALDH1A1GAAMAPTKMT2A
SCHEMBL20924880 0.80 POLB (0.46) ALOX12HPGDALDH1A1GAAMAPT
SCHEMBL183463 0.79 ALDH1A1 (0.59) HPGDALDH1A1GAAMAPTKMT2A
SCHEMBL1403667 0.79 ALOX12 (0.58) ALOX12HPGDALDH1A1GAAMAPT
SCHEMBL6307134 0.78 NPC1 (0.59) HPGDALDH1A1GAAMAPTKMT2A
SCHEMBL21507878 0.78 KMT2A (0.40) ALOX12HPGDALDH1A1GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3901131-A1 METHOD FOR PRODUCING AMINE THROUGH REDUCTION OF AMIDE Takasago International Corporation (JP) 2021-10-27 EP disclosed
EP-3611176-B1 NITROGEN-CONTAINING CYCLIC COMPOUND AND COLOR-CHANGING FILM COMPRISING SAME LG CHEMICAL LTD (KR) 2021-06-02 EP disclosed
EP-3782986-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2021-02-24 EP disclosed
EP-3192848-B1 ORGANIC LIGHT EMITTING DIODE LG CHEMICAL LTD (KR) 2020-08-12 EP disclosed
EP-3693362-A1 PARASITIC PLANT GERMINATION REGULATOR National University Corporation Nagoya University (JP) 2020-08-12 EP disclosed
EP-2427451-B1 ALPHA HELIX MIMETICS AND METHODS RELATING THERETO PRISM BIOLAB CO LTD (JP) 2019-03-20 EP disclosed
EP-2887943-B1 NOVEL 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES VIROSTATICS SRL (IT) 2017-12-06 EP disclosed
EP-3192848-A1 ORGANIC LIGHT EMITTING DIODE LG Chem, Ltd. (KR) 2017-07-19 EP disclosed
EP-3124519-A1 COPOLYMER AND ORGANIC SOLAR CELL COMPRISING SAME LG Chem, Ltd. (KR) 2017-02-01 EP disclosed
US-9416080-B2 Catalytic C—H bond activation GEORGETOWN UNIVERSITY (US) 2016-08-16 US disclosed
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-20150321982-A1 Catalytic C-H Bond Activation NATIONAL SCIENCE FOUNDATION 2015-11-12 US disclosed
EP-1575940-B1 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER NOVARTIS AG (CH) 2011-10-05 EP disclosed
EP-1105413-B1 HEPATITIS C INHIBITOR TRI-PEPTIDES BOEHRINGER INGELHEIM CA LTD (CA) 2009-04-29 EP disclosed
WO-2008112156-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS (US) 2008-09-18 WO disclosed
WO-2008045535-A2 CONVERTIBLE NUCLEOSIDE DERIVATIVES RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2008-04-17 WO disclosed
WO-2005030725-A1 DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION GLAXO GROUP LIMITED (GB) 2005-04-07 WO disclosed
EP-0736037-A1 NOVEL INTERMEDIATES FOR THE SYNTHESIS OF L-ASPARTYL-D-$g(a)-AMINOALKANOYL-(S)-N-$g(a)-ALKYLBENZYL AMIDES USEFUL AS ARTIFICIAL SWEETENERS THE COCA-COLA COMPANY (US) 1996-10-09 EP disclosed
EP-0127802-B1 META- AND PARA-ISOPROPENYL-ALPHA,ALPHA-DIMETHYLBENZYLAMINE AMERICAN CYANAMID COMPANY (US) 1988-04-20 EP disclosed
EP-0127802-A2 Meta- and para-isopropenyl-alpha,alpha-dimethylbenzylamine AMERICAN CYANAMID COMPANY (US) 1984-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150321982-A1 Catalytic C-H Bond Activation CBR3, CBR1, SOD3 ALOX12 1628/4885HPGD 2541/4885ALDH1A1 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.